Cytosorbents Corp.
- CTSO · Nasdaq
- Surgical & Medical Instruments & Apparatus
- Princeton, NJ
- 129 employees
- CIK 0001175151
Updated from SEC filings through
Top things to know
Executives
-
Phillip P. Chan Chief Executive Officer 4, 2026-09-16 -
Peter J. Mariani Chief Financial Officer 4, 2026-06-16 - Kathleen P. Bloch Chief Financial Officer 10-K, 2026-03-30
- Kathy Bloch former CFO 10-K, 2026-03-30
-
Vincent Capponi President and COO 4, 2026-09-16 -
Efthymios N. Deliargyris Chief Medical Officer DEF 14A, 2026-06-25
Cytosorbents Corp is a U.S. public company in surgical & medical instruments & apparatus (SIC 3841), headquartered in Princeton, NJ. It trades as CTSO on Nasdaq. Revenue was $37.1M in the fiscal year ending December 31, 2025, +4.1% from the year before. It reported about 129 employees. Phillip P. Chan is Chief Executive Officer.
Five-year financials
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $37.1M 10-K, 2026-03-30 | $35.6M 10-K, 2026-03-30 | $31.1M 10-K, 2025-03-31 | $34.7M 10-K, 2024-03-15 | $43.2M 10-K, 2024-03-15 |
| Operating income | -$14.7M 10-K, 2026-03-30 | -$16.5M 10-K, 2026-03-30 | -$31.9M 10-K, 2025-03-31 | -$31.5M 10-K, 2024-03-15 | -$22.7M 10-K, 2024-03-15 |
| SG&A | $35.6M 10-K, 2026-03-30 | $33.7M 10-K, 2026-03-30 | $38.3M 10-K, 2025-03-31 | $34.3M 10-K, 2024-03-15 | $35.8M 10-K, 2024-03-15 |
| Net income | -$8.2M 10-K, 2026-03-30 | -$20.7M 10-K, 2026-03-30 | -$29.2M 10-K, 2025-03-31 | -$32.8M 10-K, 2024-03-15 | -$24.6M 10-K, 2024-03-15 |
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| Phillip P. Chan Chief Executive Officer at CytoSorbents Corporation | Chief Executive Officer | 4, 2026-09-16 |
| Peter J. Mariani Experienced Life Science CFO & EVP | Strategic Advisor in Public & Pre-IPO Companies | Chief Financial Officer | 4, 2026-06-16 |
| Kathleen P. Bloch | Chief Financial Officer | 10-K, 2026-03-30 |
| Kathy Bloch | former CFO | 10-K, 2026-03-30 |
| Vincent Capponi | President and COO | 4, 2026-09-16 |
| Efthymios N. Deliargyris | Named in proxy bio: Chief Medical Officer | DEF 14A, 2026-06-25 |
| Vincent J. Capponi | Named in proxy bio: MS | DEF 14A, 2026-06-25 |
| Alan D. Sobel | Board member (per proxy) bio: CPA | DEF 14A, 2026-06-25 |
| Edward R. Jones | Board member (per proxy) bio: MD, MBA | DEF 14A, 2026-06-25 |
| Efthymios Deliargyris | Board member (per proxy) bio: MD | DEF 14A, 2026-06-25 |
| Jiny Kim | Board member (per proxy) bio: MBA | DEF 14A, 2026-06-25 |
What Cytosorbents Corp does
We are a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery through blood purification. CytoSorbents’ proprietary blood purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption.g.
Item 1. Business, 10-K for the year ending December 31, 2025
Shares and governance
| Shares outstanding | 62.8 million (as of July 31, 2026) | 10-Q, August 6, 2026 |
|---|---|---|
| Public float | $60.6M (as of June 30, 2025) | 10-K/A, April 15, 2026 |
| Reportable segments | 1 (period ending June 30, 2026) | 10-Q, August 6, 2026 |
| Latest proxy statement | Meeting August 13, 2026 (filed June 25, 2026) | DEF 14A, June 25, 2026 |
| Auditor | WithumSmith+Brown, PC (East Brunswick, New Jersey) | Latest 10-K |
Insider trades
Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.
| Date | Insider | Trade | Shares | Value | Source |
|---|---|---|---|---|---|
| September 15, 2026 | Phillip P. Chan Chief Executive Officer | Buy | 3,774 | $23K | Form 4, September 16, 2026 |
| September 15, 2026 | Alan D. Sobel Director | Buy | 2,500 | $15K | Form 4, September 16, 2026 |
| September 14, 2026 | Vincent Capponi President and COO | Buy | 2,073 | $13K | Form 4, September 16, 2026 |
| September 4, 2026 | Phillip P. Chan Chief Executive Officer | Buy | 200,000 | $70K | Form 4, September 9, 2026 |
| June 15, 2026 | Peter J. Mariani Chief Financial Officer | Buy | 100,000 | $44K | Form 4, June 16, 2026 |
| June 15, 2026 | Phillip P. Chan Chief Executive Officer | Buy | 261,469 | $105K | Form 4, June 15, 2026 |
Recent 8-K events
- 8-K filed 2026-09-23
- Item 7.01 Regulation FD disclosure
- Item 8.01 Other events
- 8-K filed 2026-09-08
- Item 5.03 Amendments to articles or bylaws; change in fiscal year
- 8-K filed 2026-08-14
- Item 5.07 Submission of matters to a vote of security holders
- 8-K filed 2026-08-07
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-08-06
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-07-06
- Item 3.01 Notice of delisting or failure to meet listing standards
- 8-K filed 2026-06-25
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-05-13
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-04-02
- Item 3.01 Notice of delisting or failure to meet listing standards
- 8-K filed 2026-03-25
- Item 2.02 Results of operations and financial condition (earnings release)
- Item 7.01 Regulation FD disclosure
Frequently asked questions about Cytosorbents Corp
- What does Cytosorbents Corp do?
- In its own words, from Item 1 of its 10-K: "We are a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery through blood purification. CytoSorbents’ proprietary blood purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption.g."
- What is Cytosorbents Corp's revenue?
- $37.1M for the fiscal year ending December 31, 2025, from its 10-K filed March 30, 2026.
- Is Cytosorbents Corp profitable?
- Cytosorbents Corp reported net income of -$8.2M for the fiscal year ending December 31, 2025.
- How many employees does Cytosorbents Corp have?
- About 129 as of December 31, 2025, as stated in its annual report.
- Who is the CEO of Cytosorbents Corp?
- Phillip P. Chan, Chief Executive Officer, as named in a 4 filed September 16, 2026.
- Who is the CFO of Cytosorbents Corp?
- Peter J. Mariani, Chief Financial Officer, as named in a 4 filed June 16, 2026.
- Where is Cytosorbents Corp headquartered?
- Princeton, NJ.
- What is Cytosorbents Corp's stock ticker?
- CTSO on Nasdaq.
- What industry is Cytosorbents Corp in?
- Surgical & Medical Instruments & Apparatus, SIC code 3841.
- What is Cytosorbents Corp's website?
- cytosorbents.com.
- When does Cytosorbents Corp report earnings next?
- November 12, 2026 at 16:30. Source: ir_events.
- Is Cytosorbents Corp a public company?
- Yes. Cytosorbents Corp files with the SEC under CIK 0001175151 and trades as CTSO.
- Who audits Cytosorbents Corp?
- WithumSmith+Brown, PC, East Brunswick, New Jersey, as named in its latest annual report (10-K).
- How many shares of Cytosorbents Corp are outstanding?
- 62.8 million shares as of July 31, 2026, from its 10-Q filed August 6, 2026.
- What is Cytosorbents Corp's public float?
- $60.6M as of June 30, 2025, as reported on the cover of its 10-K/A filed April 15, 2026.
- How many business segments does Cytosorbents Corp report?
- 1 reportable segment for the period ending June 30, 2026, from its 10-Q filed August 6, 2026.
- When is Cytosorbents Corp's annual shareholder meeting?
- August 13, 2026, per its proxy statement (DEF 14A) filed June 25, 2026.
- Have Cytosorbents Corp insiders traded stock recently?
- Since June 15, 2026, officers and directors reported 0 open-market sales and 6 purchases worth about $269K on Forms 4 and 5. The most recent: Phillip P. Chan (Chief Executive Officer) bought 3,774 shares on September 15, 2026.